Peptides appear in oncology both as targeting ligands and as direct-acting agents, and the two roles have very different development requirements.
Key Takeaways
- Sequences selected against tumour-associated receptors are used to direct imaging agents or cytotoxic payloads.
- The most clinically established peptide oncology drugs are hormone analogues that suppress hormone-dependent tumour growth.
- Across all these roles, the recurring limitation is achieving sufficient concentration at the tumour while sparing normal tissue.
Targeting ligands
Sequences selected against tumour-associated receptors are used to direct imaging agents or cytotoxic payloads. The value is specificity rather than potency, and internalisation behaviour matters more than affinity for this application.
Direct-acting anticancer peptides
Some cationic amphipathic peptides show preferential activity against cancer cells, often attributed to the anionic character of tumour cell membranes. Selectivity in vitro is frequently encouraging and has proven difficult to reproduce in vivo.
For related mechanism work, see peptide-drug conjugates.
Hormone analogues in cancer care
The most clinically established peptide oncology drugs are hormone analogues that suppress hormone-dependent tumour growth. Their success reflects a well-understood endocrine mechanism rather than a tumour-selective one.
Peptide cancer vaccines
Defined tumour-associated epitopes are used to drive a T-cell response, usually with adjuvants and checkpoint combinations. Clinical results have been modest, but the approach remains active because the mechanism is distinct from cytotoxic therapy.
Delivery remains the constraint
Across all these roles, the recurring limitation is achieving sufficient concentration at the tumour while sparing normal tissue. That is a delivery problem more often than a potency problem, and it shapes which programmes are realistic.
Experimental Conditions and Practical Setup
Targeting peptides are characterised by internalisation rate and by uptake in target versus non-target cells, rather than by affinity alone. Direct-acting peptides are assessed with a parallel non-malignant cell line, because apparent tumour selectivity in a single-line comparison frequently narrows once additional lines and serum-containing conditions are included.
Oncology peptide roles and their development demands
| Role | Key attribute | Main obstacle |
|---|---|---|
| Targeting ligand | Internalisation and specificity | Achieving sufficient tumour accumulation |
| Direct-acting agent | Selectivity over non-malignant cells | Selectivity narrows in vivo |
| Hormone analogue | Established endocrine mechanism | Limited to hormone-dependent disease |
| Cancer vaccine | T-cell response magnitude | Modest clinical results to date |
Practical Notes for the Bench
- Select targeting peptides for internalisation, not affinity alone.
- Be sceptical of in vitro selectivity claims that lack in vivo confirmation.
- Treat delivery, rather than potency, as the usual limiting factor.
Frequently Asked Questions
What is the main peptide role in oncology?
Both targeting ligand and direct-acting agent, though clinically established products are largely hormone analogues.
Why do cationic anticancer peptides fail in vivo?
Selectivity seen in culture usually narrows considerably once serum binding and pharmacokinetics are taken into account.
Are peptide cancer vaccines effective?
Results to date have been modest, and the approach is generally studied in combination with checkpoint blockade.
Why is delivery usually the limiting factor?
Because potency is often adequate while achievable concentration at the tumour is not. That makes it a delivery problem rather than a molecule design problem.
Related Reading
- peptide-drug conjugates
- generic peptide development
- peptide drug candidate criteria
- peptide cleavage deprotection
- peptide sustained release
References & Further Reading
- Ehsan S et al. Mitochondrial Targeting Peptide-based Nanodelivery for Cancer Treatment. Curr Protein Pept Sci. 2022. PubMed 35619295
- Zhang D et al. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. EBioMedicine. 2024. PubMed 38954976
- Alas M et al. Peptide-Drug Conjugates with Different Linkers for Cancer Therapy. J Med Chem. 2021. PubMed 33382619
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
Educational content for research staff. Nothing here should be read as advice on human or veterinary use of any compound.
Reviewed by Dr. Aiko Tanaka, Bioactive Peptides & Dermatological Research.